MedTrace Logo

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

NCT04876755 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-05-06

No results posted yet for this study

Summary

This is an open label trial to assess the efficacy of MBM-02 (Tempol) as a treatment for patients diagnosed with prostate cancer in biochemical recurrence.

Conditions

  • Prostate Cancer Recurrent
  • Biochemical Recurrent Prostate Cancer

Interventions

DRUG

MBM-02

MBM-02 is an HIF-1 and HIF-2 inhibitor.

Sponsors & Collaborators

  • Prostate Oncology Specialists

    collaborator UNKNOWN

  • Matrix Biomed, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2022-09-30
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04876755 on ClinicalTrials.gov